Literature DB >> 6401084

Aspirin-induced hearing loss as a model of sensorineural hearing loss.

D McFadden1, H S Plattsmier, E G Pasanen.   

Abstract

Performance in forward-masking, temporal-integration, and gap-detection tasks was measured in five normal-hearing subjects before and during a five-day period of aspirin use. The drug regimen was 3.9 g per day, taken in four equal doses at 6-h intervals. In the subjects showing substantial temporary hearing loss induced by the aspirin, (1) forward masking declined at about a normal rate as the masker-to-signal interval was increased, (2) the temporal-integration functions were flatter than normal, and (3) detection of a temporal gap was worse than normal at low sound-pressure levels (SPLs) but was essentially normal at levels above about 60 dB SPL. These aspirin-induced changes in performance are similar to the differences observed between normal listeners and listeners with mild sensorineural hearing loss. Thus, temporary, aspirin-induced hearing loss offers promise as a model condition for sensorineural hearing loss. The advantages offered by this model include all those typically attributed to within-subjects experimental designs, as well as the ability to manipulate the amount of hearing loss. Its primary disadvantages are that the hearing loss is not asymmetrically distributed toward the high-frequency region, as it typically is with sensorineural deafness, and there are large individual differences in the amount of temporary hearing loss induced by fixed doses of aspirin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6401084     DOI: 10.1016/0378-5955(84)90114-x

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  29 in total

1.  Effects of low-frequency biasing on spontaneous otoacoustic emissions: amplitude modulation.

Authors:  Lin Bian; Kelly L Watts
Journal:  J Acoust Soc Am       Date:  2008-02       Impact factor: 1.840

Review 2.  Impact of nonaspirin nonsteroidal anti-inflammatory agents and acetaminophen on sensorineural hearing loss: a systematic review.

Authors:  Meghann E Kyle; James C Wang; Jennifer J Shin
Journal:  Otolaryngol Head Neck Surg       Date:  2015-01-05       Impact factor: 3.497

3.  Too much of a good thing: long-term treatment with salicylate strengthens outer hair cell function but impairs auditory neural activity.

Authors:  Guang-Di Chen; Mohammad Habiby Kermany; Alessandra D'Elia; Massimo Ralli; Chiemi Tanaka; Eric C Bielefeld; Dalian Ding; Donald Henderson; Richard Salvi
Journal:  Hear Res       Date:  2010-03-06       Impact factor: 3.208

4.  Sodium salicylate alters temporal integration measured through increasing stimulus presentation rates.

Authors:  Nicole J Wood; Andrea S Lowe; Joseph P Walton
Journal:  Int J Audiol       Date:  2019-03       Impact factor: 2.117

5.  Effect of salicylate on KCNQ4 of the guinea pig outer hair cell.

Authors:  T Wu; P Lv; H J Kim; E N Yamoah; A L Nuttall
Journal:  J Neurophysiol       Date:  2010-02-10       Impact factor: 2.714

6.  Salicylate selectively kills cochlear spiral ganglion neurons by paradoxically up-regulating superoxide.

Authors:  Lili Deng; Dalian Ding; Jiping Su; Senthilvelan Manohar; Richard Salvi
Journal:  Neurotox Res       Date:  2013-03-15       Impact factor: 3.911

Review 7.  Otoacoustic emissions: a new method to diagnose hearing impairment in children.

Authors:  P G Zorowka
Journal:  Eur J Pediatr       Date:  1993-08       Impact factor: 3.183

8.  Does tinnitus "fill in" the silent gaps?

Authors:  Jennifer Campolo; Edward Lobarinas; Richard Salvi
Journal:  Noise Health       Date:  2013 Nov-Dec       Impact factor: 0.867

Review 9.  Ototoxicity associated with salicylates. A brief review.

Authors:  J A Brien
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 10.  Salicylate-induced cochlear impairments, cortical hyperactivity and re-tuning, and tinnitus.

Authors:  Guang-Di Chen; Daniel Stolzberg; Edward Lobarinas; Wei Sun; Dalian Ding; Richard Salvi
Journal:  Hear Res       Date:  2012-11-27       Impact factor: 3.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.